Manejo da Anemia Falciforme em Crianças no Atendimento de Emergência: uma revisão de literatura
DOI:
https://doi.org/10.36557/2674-8169.2026v8n1p258-277Palavras-chave:
Anemia Falciforme;, emergência, criançaResumo
A anemia falciforme é uma doença genética hereditária caracterizada pela formação anômala das hemácias, que assumem um formato em foice. Essa alteração provoca as crises dolorosas, uma das principais manifestações da doença. Um grande desafio no manejo da anemia falciforme é na infância, já que para a criança e para o médico é difícil identificar e quantificar a dor, especialmente em contextos de emergência. O objetivo desse estudo foi esclarecer a abordagem da anemia falciforme no atendimento a pacientes pediátricos na emergência. Foi realizada uma busca nas plataformas PubMed, Biblioteca Virtual em Saúde (BVS) e Cochrane, os descritores utilizados foram “sickle cell”, “emergency” e “children”, utilizando o operador booleano “AND”. Foram incluídos no estudo artigos publicados nos últimos 10 anos (2014-2024); com texto completo e artigos cujos estudos eram do tipo ensaio clínico e ensaio clínico controlado e foram excluídos os artigos fora do tema abordado e os artigos duplicados entre as bases de dados. Um total de 26 artigos científicos foram analisados. Seis estudos demonstraram que o uso da argenina é importante para a redução da dor. Outros cinco estudos mostraram que o uso de fentanil intranasal deve ser o tratamento inicial para o paciente. Cinco estudos apontaram que a implementação de um plano padronizado, que permite a quantificação da dor do paciente e o uso dos medicamentos na primeira hora, é crucial para o atendimento na emergência. Oito estudos demonstraram a ineficácia do uso de magnésio intravenoso, pasugrel, adesivo de lidocaína a 5%, solução salina aquecida, paracetamol intravenoso, ticagrelor e oxido nítrico inalado. Através dos estudos analisados foi observado que a implementação de um plano padronizado é fundamental para a abordagem do paciente, além do uso de argenina e do fentanil intranasal na primeira hora de atendimento.
Downloads
Referências
- Dia mundial de conscientização sobre a doença falciforme [Internet]. Empresa Brasileira de Serviços Hospitalares; 2024. Available from: https://www.gov.br/ebserh/pt-br/hospitais-universitarios/regiao-sudeste/hc-ufu/comunicacao/noticias/dia-mundial-de-conscientizacao-sobre-a-doenca-falciforme-1
- RELATÓRIO PARA SOCIEDADE [Internet]. Available from: https://www.gov.br/conitec/pt-br/midias/relatorios/2024/sociedade/20240803_437_ReSoc_Hidroxiureia_Preveno_de_crises_2_anos.pdf
- Krishnamurti L, Smith-Packard B, Gupta A, Campbell M, Gunawardena S, Saladino R. Impact of individualized pain plan on the emergency management of children with sickle cell disease. Pediatr Blood Cancer. 2014 Jun 24;61(10):1747–53.
- Glassberg J. Evidence-based management of sickle cell disease in the emergency department. Emerg Med Pract. 2011; 13:1–20.
- Glassberg JA, Tanabe P, Chow A, Harper K, Haywood C, DeBaun MR, et al. Emergency provider analgesic practices and attitudes toward patients with sickle cell disease. Ann Emerg Med. 2013 Oct;62(4):293–302.e10.
- Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers [Internet]. 2018 Mar 15;4(1):1-22. Available from: https://www.nature.com/articles/nrdp201810
- Lobo C, Marra VN, Silva RMG. Crises dolorosas na doença falciforme. Rev Bras Hematol Hemoter. 2007 Sep;29(3):247-58.
- OMS. Anemia falciforme | Biblioteca Virtual em Saúde MS [Internet]. Saude.gov.br; 2024. Available from: https://bvsms.saude.gov.br/anemia-falciforme/#:~:text=%E2%80%93%20Crise%20de%20dor:%20%C3%A9%20o
- Dias TL, Oliveira CGT de, Enumo SRF, Paula KMP de. A dor no cotidiano de cuidadores e crianças com anemia falciforme. Psicologia USP. 2013 Dec;24(3):391–411.
- Karkoska K, Appiah‐Kubi A, Rocker J, Stoffels G, Aygun B. Management of vaso‐occlusive episodes in the day hospital decreases admissions in children with sickle cell disease. Br J Haematol. 2019 May 31;186(6):855–60.
- Sousa ÉQ de, Sales AA, Santos CV de S, Andrade SM de, Neto MPL, Oliveira EH. Uso da hidroxiuréia na anemia falciforme: uma revisão da literatura. Res Soc Dev. 2020 Jan 1;9(2):2525-3409.
- Brasília, DF | fevereiro de 2024 [Internet]. Available from: https://www.gov.br/conitec/ptbr/midias/relatorios/2024/20240307_Relatrio_873_Hidroxiureia500mg_DOENAFALCIFORME.pdf
- Priscila E, Souza D, Silva A, Carvalho S, Rosa Cândida Cordeiro, Maria E. Cuidar de pessoas com doença falciforme na unidade de emergência: discurso de uma equipe multiprofissional. Ciênc Cuid Saúde. 2014 May 8;13(2):278–85.
- Hatabah D, Bakhsi N, Brown LA, F Harris, Leake D, Korman R, et al. Low arginine bioavailability and clinical outcomes in children with sickle cell disease hospitalized with vaso-occlusive pain episode. Blood. 2023 Nov 2;142(Suppl 1):147–7.
- Rees CA, Brousseau DC, Ahmad FA, Bennett JE, Bhatt S, Bogie A, et al. Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: a multicenter pediatric emergency medicine perspective. Am J Hematol. 2023 Feb 6;98(4):620–7.
- Onalo R, Cilliers A, Cooper P, Morris CR. Arginine therapy and cardiopulmonary hemodynamics in hospitalized children with sickle cell anemia: a prospective double-blinded randomized placebo-controlled trial. Am J Respir Crit Care Med. 2022 Apr 15 2022;206(1):70-80.
- Morris CR, Bakshi N, Leake D, Gillespie S, Brown LAS, Harris F, et al. Impact of arginine therapy on clinical outcomes, mitochondrial function and oxidative stress in children with sickle cell disease hospitalized with vaso-occlusive pain episodes: a randomized controlled trial. Blood [Internet]. 2020;136(12):1402-06
- Altawashi A, Albaroudi O, Aboursheid T, Alahdab F. Inhaled nitric oxide for treating pain crises in people with sickle cell disease. Cochrane Database Syst Rev. 2022;7(7):CD011808
- Heeney MM, Abboud MR, Githanga J, Baba Inusa, Kanter J, Michelson AD, et al. Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood. 2022 Sep 29;140(13):1470–81.
- Biemond BJ, Tombak A, Kilinc Y, Al-Khabori M, Abboud M, Nafea M, et al. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2021 May;8(5):e334-43.
- Onalo R, Cooper P, Cilliers A, Vorster BC, Uche N, Oluseyi OO, et al. Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria. Am J Hematol. 2021;96(1):89-97.
- Hood AM, Kölbel M, Stotesbury H, Kawadler J, Slee A, Inusa B, et al. Biopsychosocial predictors of quality of life in paediatric patients with sickle cell disease. Front Psychol. 2021;12:681137.
- Morris CR, Brown LAS, Reynolds M, Dampier CD, Lane PA, Watt A, et al. Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain. Blood. 2020 Sep 17;136(12):1402–6.
- Dhebaria T, Sivitz A, Tejani C. Does intravenous acetaminophen reduce opioid requirement in pediatric emergency department patients with acute sickle cell crises? Miner J, editor. Acad Emerg Med. 2021;28(6):639-46.
- Brousseau DC, Alpern ER, Chamberlain JM, Ellison AM, Bajaj L, Cohen DM, et al. A multiyear cross-sectional study of guideline adherence for the timeliness of opioid administration in children with sickle cell pain crisis. Ann Emerg Med. 2020 Sep;76(3)-11-13.
- Quarrie RP, Stoner MJ, Choueiki JM, Bonsu BK, Cohen DM. Clinical impact of warmed intravenous saline in sickle cell patients with vasoocclusive episodes. Pediatr Emerg Care. 2020 May;36(5):229–35.
- Butt Z, Chakravorty S. Use of fluid and oxygen therapy in normoxaemic paediatric patients presenting with acute sickle vaso-occlusive episodes requiring hospital admission and analysis of clinical outcome. Blood. 2019 Nov 13;134(Suppl 1):4844-4844.
- Rousseau V, Morelle M, Arriuberge C, Darnis S, Chabaud S, Launay V, et al. Efficacy and tolerance of lidocaine 5% patches in neuropathic pain and pain related to vaso-occlusive sickle cell crises in children: a prospective multicenter clinical study. Pain Pract. 2018 Feb 28;18(6):788–97.
- Shiva S, Brown LA, Wang Y, Dampier C, Watt A, Tripathi V, et al. Parenteral L-Arginine improves mitochondrial function in children with sickle cell disease admitted for vaso-occlusive pain episodes. Blood [Internet]. 2018; 132:508.
- Rees CA, Brousseau DC, Cohen DM, Villella A, Dampier C, Brown KM, et al. Sickle cell disease treatment with arginine therapy (STArT): study protocol for a phase 3 randomized controlled trial. Trials. 2023 Aug 17;24(1):538-42.
- Hulbert ML, Panepinto JA, Scott JP, Liem RI, Cook LJ, Simmons T, et al. Red blood cell transfusions during sickle cell anemia vaso-occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion. 2017 May 12;57(8):1891–7.
- Fein DM, Avner JR, Scharbach K, Manwani D, Khine H. Intranasal fentanyl for initial treatment of vaso-occlusive crisis in sickle cell disease. Pediatr Blood Cancer. 2016 Nov 10;64(6)1102-06.
- Brandow AM, Nimmer M, Simmons T, Charles Casper T, Cook LJ, Chumpitazi CE, et al. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. Am J Hematol. 2016 Sep 3;91(12):1175–80.
- Morris CR, Ahmad F, Bennett J, Bhatt S, Bogie A, Brown KM, et al. Pediatric emergency department use of intranasal fentanyl to treat pain in children with sickle cell disease and its impact on discharge rates: a multicenter perspective. Blood. 2016;128(22):1306-10.
- Brousseau DC, Scott J, Badaki-Makun O, Darbari DS, Chumpitazi CE, Airewele G, et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood. 2015 Oct 1;126(14):1651–7.
- Kavanagh PL, Sprinz PG, Wolfgang TL, Killius K, Champigny M, Sobota A, et al. Improving the management of vaso-occlusive episodes in the pediatric emergency department. Pediatrics [Internet]. 2015 Oct 1;136(4):1016-25.
- Hoppe CC, Styles L, Heath LE, Zhou C, Jakubowski JA, Winters KJ, et al. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell. Pediatr Blood Cancer. 2015 Sep 24;63(2):299–305.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Maria Victória Farfan, Diego Rodrigues Vieira , Ana Clara Pinheiro de Andrade, Camila Trotta Lourenço de Lemos, Gustavo Alves Henderson Cardoso, Joao Vitor Macedo de Oliveira , Juliana Silveira Sola, Luan Gabriel Affonso, Milla Daudt Ribeiro
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os autores são detentores dos direitos autorais mediante uma licença CCBY 4.0.
